SNY Jan 2024 52.500 put
| Previous close | 4.0000 |
| Open | N/A |
| Bid | 2.2500 |
| Ask | 6.0000 |
| Strike | 52.50 |
| Expiry date | 2024-01-19 |
| Day's range | 4.0000 - 4.0000 |
| Contract range | N/A |
| Volume | |
| Open interest | 17 |
- Motley Fool
Is This Pharma Duo on the Brink of Another Billion-Dollar Opportunity?
On March 23, Sanofi (NASDAQ: SNY) and Regeneron's (NASDAQ: REGN) Dupixent shared positive results in its phase 3 clinical trial of patients with uncontrolled, chronic obstructive pulmonary disease (COPD). Let's take a look at the clinical data and the global COPD market to assess the sales potential of the drug.
- GlobeNewswire
Press Release: Availability of the Q1 2023 Memorandum for modelling purposes
Availability of the Q1 2023 Memorandum for modelling purposes Paris, France – March 30, 2023 - Sanofi announced today that its Q1 2023 Memorandum for modelling purposes is available on the "Investors" page of the company's website: https://www.sanofi.com/en/investors/financial-results-and-events/financial-results/Q1-results-2023 As for each quarter, Sanofi prepared this document to assist in the financial modelling of the Group's quarterly results. This document includes a reminder on various no
- Zacks
Sanofi (SNY) Outpaces Stock Market Gains: What You Should Know
Sanofi (SNY) closed at $53.22 in the latest trading session, marking a +1.16% move from the prior day.
